Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Step by step instructions to Pick an Incineration Urn: Variables to Consider - 2'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- 3Kids with smartphones by age 12 are at higher risk of health issues, study finds
- 4How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
- 5Compassion and Association: Building Significant Connections
- Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- A Manual for SUVs with Less Noteworthy Gas Mileage
- Dirty soda started as a Mormon alternative to booze. Now it's everywhere.
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Watch Chinese astronauts enjoy '1st ever space BBQ' from Tiangong's brand-new oven (video)
- Figure out How to Augment Eco-friendliness in Your Volvo XC40
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
